Interestingly, in both EGFR and Anxa2 high expression groups, E-cadherin presented a significantly higher rate of low expression (Table 2, P = 0.0002), which indicates a combined effect of EGFR and Anxa2 on breast cancer EMT. This evidence concerns the gene CDH1 and breast carcinoma.